Clinical trials on Heart failure

Understanding Heart Failure: An Overview

Heart failure, often referred to as congestive heart failure, is a chronic condition where the heart muscle is unable to pump blood as well as it should. This inefficiency can lead to a buildup of fluid in the lungs and surrounding body tissues, leading to the characteristic symptoms of fatigue, shortness of breath, and swelling in the legs, ankles, and feet. Heart failure is a serious medical condition that requires management under a healthcare provider’s guidance to improve quality of life and outcomes.

Causes and Risk Factors

  • Coronary Artery Disease: The most common cause, where arteries that supply blood to the heart muscle become narrowed.
  • High Blood Pressure: Forces your heart to work harder than normal, eventually weakening it to the point it cannot pump blood efficiently.
  • Previous Heart Attack: Can leave scar tissue that interferes with the heart muscle’s ability to function.
  • Conditions like diabetes, obesity, and severe anemia can also contribute to the risk of developing heart failure.

Management and Treatment

While heart failure is a chronic condition, early diagnosis and proper management can significantly improve the quality of life. Treatment typically involves a combination of medication, lifestyle changes, and in some cases, surgery or medical devices to help the heart beat more efficiently. Medications may include ACE inhibitors, beta-blockers, and diuretics to reduce the heart’s workload and manage symptoms. Lifestyle changes such as maintaining a healthy weight, engaging in regular physical activity, and reducing sodium intake are also crucial in managing heart failure.

Understanding heart failure and its implications is the first step towards effective management. With the right treatment plan and lifestyle adjustments, individuals with heart failure can lead fulfilling lives. It’s essential to work closely with healthcare providers to tailor a treatment plan that best suits individual needs and conditions.

Prognosis for Heart Failure: Understanding Long-Term Outcomes

Heart failure is a chronic condition where the heart struggles to pump blood effectively throughout the body. The long-term prognosis for heart failure varies widely and depends on several factors, including the severity of the condition, underlying causes, and overall health. While heart failure is a progressive disease that tends to worsen over time, early diagnosis and careful management can improve quality of life and potentially slow progression. Many patients with heart failure lead full, active lives with the help of medical management. However, in advanced stages, the condition can significantly impact daily activities and may lead to serious health complications. Life expectancy for individuals with heart failure is highly individualized; some may experience a stable condition for many years, while others may face a decline in health more rapidly. Continuous monitoring and regular follow-up with healthcare providers are crucial for managing heart failure.

Complications in Heart Failure

Heart failure can lead to several complications that may affect daily activities and overall well-being. Fluid buildup is common, which can cause swelling in the legs and ankles, and make breathing difficult. This condition, known as pulmonary edema, can lead to fatigue and shortness of breath, even during periods of rest. The heart’s struggle to pump blood efficiently might also result in a rapid or irregular heartbeat, which can be unsettling and may increase the risk of a stroke. Kidney damage or failure can occur since the kidneys do not receive enough blood to function properly. This can lead to a dangerous buildup of waste in the body and might necessitate dialysis. Additionally, heart failure can weaken the immune system, making it more challenging to fight off infections, which can further impact health and quality of life.

Treatment Methods for Heart Failure

In the management of heart failure, lifestyle modifications are crucial. A heart-healthy diet, low in salt, saturated fats, and cholesterol, is recommended to support cardiac function. Regular physical activity, tailored to individual capabilities, can improve cardiovascular health and endurance. Weight management is also important to reduce the strain on the heart.

Pharmacotherapy is a cornerstone of heart failure management. Medications may include ACE inhibitors, beta-blockers, diuretics, and aldosterone antagonists, which work together to alleviate symptoms and improve heart function. Adherence to prescribed medication regimens is essential, and consultation with healthcare providers for personalized treatment plans is advised.

Modern technology offers additional support. Remote monitoring devices can track vital signs and symptoms, enabling timely medical interventions. Wearable technology can encourage physical activity and provide feedback on progress. Smartphone applications can assist with medication adherence and lifestyle tracking, ensuring engagement in the treatment plan is maintained.

  • CT-EU-00029829

    Study of the effectiveness of a new drug in the treatment of heart failure and pulmonary hypertension

    This clinical trial explores the potential benefits of AZD3427 for individuals with heart failure (HF) and pulmonary hypertension (PH) Group 2, a condition characterized by increased blood pressure in the lungs due to heart disease. Around 220 participants will be randomly assigned to receive either AZD3427 or a placebo through subcutaneous injections every two weeks for 24 weeks. The trial aims to assess the impact of AZD3427 on reducing pulmonary vascular resistance (PVR) and improving various heart and lung health indicators. Participants will undergo multiple study visits, with the total duration of the study being approximately 32 to 37 weeks.

    • AZD3427- new potential medication for heart failure and pulmonary hypertension
  • Examining Ziltivekimab’s potential for heart failure and inflammation treatment

    This is a study about a possible treatment for people with heart trouble and inflammation. In this trial, it is included the medicine called ziltivekimab. Participants will be divided into groups. One of them will get ziltivekimab and some will get a placebo. The study will last up to 4 years and patients will have to come to the clinic as many as 20 times. It will be used in an app on the patient’s phone to keep track of the treatment and get information about how they are doing. The things like the number of events (like hospital visits), and how many months go by will be measurable. The KCCQ (Kansas City Cardiomyopathy Questionnaire) will also be utilized to determine the extent of well-being in managing heart disease and its impact on life.

    • Ziltivekimab
  • New approach to treating swelling in heart failure patients

    This innovative study focuses on improving treatment for patients with heart failure who are experiencing fluid overload. It involves using water pills (diuretics) in a novel way, guided by regularly checking the salt (sodium) levels in patients’ urine. By monitoring these levels, doctors can adjust the diuretic dosage more accurately, aiming to remove the right amount of excess fluid from the body. This tailored approach seeks to optimize the treatment process, alleviate symptoms like swelling and shortness of breath more effectively, and enhance the overall health and comfort of patients with acute heart failure. The study’s careful tracking and personalized treatment strategy promise to offer valuable insights into managing this challenging condition.

    • potassium
    • canrenoate
    • chlorthalidone
    • bumetanide
    • acetazolamide
  • Evaluating safety & effects of new therapy in Heart Failure

    This research focuses on investigating a new medication, REGN5381, for adults experiencing heart-related issues and considering a specialized heart procedure known as right heart catheterization, as recommended by the study’s doctor. The primary objectives include assessing the safety and tolerability of the study medicine, understanding the changes that may occur in the body due to its administration, measuring the concentration of the study medicine in the blood at different intervals, and examining whether the body generates defense mechanisms (antibodies) against the study medicine, potentially impacting its efficacy or causing physiological changes.

    • REGN5381- new potential medication for hypertension and congestive heart failure
  • Study on heart failure treatment using continuous intravenous infusion with Alprostadil

    This is a study about a heart failure medicine called Alprostadil (ALP-1). The study aims to assess the efficacy of ALP-1 in individuals experiencing severe heart failure, encompassing approximately 700 patients worldwide not anticipated to undergo heart transplant or receive a specialized heart pump within the next 6 months. Patients will be administered either ALP-1 or a placebo through continuous infusion until the study’s conclusion, contingent upon the patient’s tolerance. The primary comparison will involve evaluating the incidence of deaths, heart transplants, or heart pump placements between the two groups. The initial 70 patients will undergo close observation to assess their response to treatment and the feasibility of adhering to study instructions. Patient selection criteria include stability, outpatient status, or recent hospital discharge, along with a stable dosage of diuretics and appropriate doses of other heart failure therapies, as determined by the treating physician.

    • Alprostadil/ALP-1
  • A study on a new drug to regulate potassium levels in heart patients treated with spironolactone

    This study is designed to evaluate the efficacy of Sodium Zirconium Cyclosilicate (SZC) in individuals with heart disease who are prescribed spironolactone and exhibit elevated potassium levels. The objective is to assess whether SZC is superior to a placebo in maintaining normal potassium levels while administering spironolactone. This research comprises three stages. The initial phase involves a medical evaluation, followed by a 4 to 6-week period to determine the appropriate dosages of SZC and spironolactone for each participant. The third phase spans 6 months, during which participants are randomly assigned to receive either the genuine SZC medication or a placebo.

    • Spironolactone
    • Sodium zirconium cyclosilicate
  • Understanding the effectiveness and safety of new treatment for heart function after myocardial infarction

    This is a study evaluating the safety and effectiveness of the treatment CDR132L in patients who’ve suffered from a myocardial infarction. The study focuses on assessing whether CDR132L can improve heart function and prevent complications in patients who have had heart attacks and currently have reduced left ventricular ejection fraction. Left ventricular ejection fraction is a measure of the heart’s ability to pump blood to the rest of the body and is an important indicator of heart function. In the study, patients will be randomly assigned to two groups: one group will receive CDR132L, and the other group will receive a placebo. Throughout the study, patients will undergo regular examinations, follow-up visits, and laboratory tests to monitor their health status and assess the effectiveness of the drug.

    • CDR132L